Elk Creek Partners LLC raised its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 0.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 552,656 shares of the company’s stock after acquiring an additional 540 shares during the quarter. Pacira Pharmaceuticals comprises 1.7% of Elk Creek Partners LLC’s holdings, making the stock its 8th largest position. Elk Creek Partners LLC owned 1.38% of Pacira Pharmaceuticals worth $26,362,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its holdings in Pacira Pharmaceuticals by 5.2% in the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after acquiring an additional 270 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Pacira Pharmaceuticals by 12.2% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after acquiring an additional 303 shares during the period. Denver Investment Advisors LLC raised its holdings in Pacira Pharmaceuticals by 6.8% in the 2nd quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after acquiring an additional 435 shares during the period. Amalgamated Bank raised its holdings in Pacira Pharmaceuticals by 12.7% in the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after acquiring an additional 566 shares during the period. Finally, Legal & General Group Plc raised its holdings in Pacira Pharmaceuticals by 5.3% in the 2nd quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock valued at $620,000 after acquiring an additional 653 shares during the period.

Pacira Pharmaceuticals, Inc. (PCRX) traded down 2.11% during mid-day trading on Friday, hitting $37.05. 712,550 shares of the company traded hands. The firm has a 50 day moving average of $37.12 and a 200 day moving average of $44.48. The firm’s market capitalization is $1.49 billion. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). The business had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 earnings per share. Equities research analysts expect that Pacira Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.

In related news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at approximately $5,788,794.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the sale, the director now directly owns 3,518 shares in the company, valued at approximately $127,175.70. The disclosure for this sale can be found here. Insiders have sold a total of 33,390 shares of company stock worth $1,215,480 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.

WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/16/pacira-pharmaceuticals-inc-pcrx-is-elk-creek-partners-llcs-8th-largest-position.html.

Several research analysts have weighed in on PCRX shares. Canaccord Genuity lowered their price target on shares of Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, August 29th. CIBC started coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. They issued a “market perform” rating on the stock. Mizuho reissued a “buy” rating and issued a $54.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Jefferies Group LLC reissued a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. Finally, Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, July 30th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus price target of $52.92.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.